# V1 Empirics Check — deepseek/deepseek-v3.2 (Variant C)

**Model:** deepseek/deepseek-v3.2
**Variant:** C
**Date:** 2026-03-27T11:24:58.823082

---

# Review: When the Mail Slows Down

## 1. Idea Fidelity

The paper largely pursues the original idea but makes several consequential departures from the identification strategy and data scope outlined in the Idea Manifest.

**Adhered to:**
-   Research question (USPS service standard changes → preventable hospitalizations in pharmacy deserts).
-   Primary outcome (preventable hospitalizations from County Health Rankings).
-   Quasi-experimental logic (distance-based treatment assignment).
-   Use of a triple-difference with pharmacy desert status.

**Key Departures:**
1.  **Treatment Variable Construction:** The manifest specified constructing treatment from the Federal Register rule's "mechanical distance thresholds to USPS processing facilities," using detailed PRC ZIP-pair data. The paper instead uses a coarse, researcher-created proxy: distance from county centroid to "the nearest major metropolitan area." This introduces significant measurement error and weakens the direct, mechanical link that was the core of the identification strategy.
2.  **Sample Period:** The manifest specified a panel from 2019-2023/24 (3 pre, 2-3 post). The paper uses a 2015-2024 panel (7 pre, 3 post). While more data is generally good, the event study reveals substantial pre-treatment trend differences in the early years (2015-2018), complicating the parallel trends assumption for the long panel. This deviation from the planned, tighter window around the policy change undermines the cleanest test of the hypothesis.
3.  **"Pharmacy Desert" Definition:** The manifest did not specify an operational definition. The paper's use of the bottom quartile of pharmacies per capita from 2019 CBP data is reasonable, but its static nature (not updated post-2019) could misclassify counties with pharmacy openings/closures after 2021.

Overall, the paper captures the spirit of the idea but substitutes a weaker, noisier identification strategy for the cleaner, more administrative one proposed.

## 2. Summary

This paper provides a well-powered null result: the 2021 USPS service standard degradation, which added 1-2 days to First-Class Mail delivery for remote routes, did not cause a detectable increase in county-level preventable hospitalizations, even in "pharmacy desert" counties where residents are most reliant on mail-order prescriptions. The findings suggest the healthcare system and mail-order pharmacies adapted to mitigate potential disruptions.

## 3. Essential Points

The authors must address these three critical issues before the paper can be considered for publication.

1.  **Invalid Treatment Variable and Threats to Identification:** The constructed treatment variable (distance to major metro area) is a poor proxy for the actual policy change. The policy changed standards based on drive-time distances between USPS *processing facilities*, not counties to metro areas. This mis-measurement likely attenuates estimates towards zero and introduces bias if the proxy correlates with unobservable trends in rural health outcomes. The authors must use the treatment variable described in the manifest, built from the PRC's ZIP-pair spreadsheet and actual USPS facility locations, to restore the credibility of the quasi-experiment.

2.  **Failure of Parallel Trends in the Long Panel:** The event study (Table 4) shows large, significant pre-trend coefficients for years 2015-2018 (200+). While coefficients for 2019-2021 are small and insignificant, the earlier divergence severely weakens the parallel trends assumption for the 10-year panel. The DiD estimate is a weighted average of all year-by-year effects; contamination from these early, non-parallel years biases the pooled estimate, regardless of near-term pre-trend validity. The authors must either (a) justify and defend the use of the long panel with a dynamic model that accounts for these differential trends, or (b) revert to the manifest's specification using only data from 2019 onward, where pre-trends are more credible.

3.  **Incorrect Triple-Difference Specification:** Equation (2) is misspecified. A valid triple-difference requires the full set of two-way interactions. The model includes `Slowdown × Post`, `Desert × Post`, and the triple interaction `Slowdown × Post × Desert`, but it **omits the crucial `Slowdown × Desert` term**. This term captures time-invariant differences in outcomes between high- and low-treatment pharmacy deserts. Its omission biases the triple-interaction coefficient (`β₂`). The model must be respecified as:
    `Y_ct = β₁ Slowdown_c × Post_t + β₂ Desert_c × Post_t + β₃ Slowdown_c × Desert_c + β₄ Slowdown_c × Post_t × Desert_c + γ_c + δ_t + ε_ct`

## 4. Suggestions

### A. Identification & Measurement
-   **Rebuild Treatment:** Follow the manifest. Use the PRC's 810K ZIP-pair data (or the derived 3-digit ZIP pair standards) to calculate the share of each county's mail volume (e.g., based on ZIP population weights) that shifted to a slower standard. This creates a continuous, dose-response measure (e.g., 0-39% of mail slowed) that is more nuanced and accurate than the 0/1/2 day increase.
-   **Validate Treatment:** Correlate your constructed treatment measure with actual USPS service performance data, if available (e.g., from the USPS Office of Inspector General or Postal Regulatory Commission reports). Show that counties assigned a higher "slowdown" actually experienced longer delivery times.
-   **Refine Pharmacy Desert:** Consider a dynamic measure. Use CBP data for each year (2015-2024) to classify pharmacy deserts annually. This accounts for pharmacy closures/openings post-2019, which may be endogenous to the policy or other trends.

### B. Empirical Specification
-   **Focus on the Cleanest Window:** The primary specification should be 2019-2024 (or 2019-2023) as planned in the manifest. Present the long panel (2015-2024) as a robustness check only after thoroughly addressing the pre-trend issue, perhaps by including county-specific linear trends or using the methods of Freyaldenhoven et al. (2021) on pre-event trends.
-   **Fix the Event Study:** The event study table is currently hard to interpret. Re-plot it as a standard event study graph with confidence intervals. Normalize the year before treatment (2021) to zero. This will visually underscore the parallel pre-trends (or lack thereof) and the null post-effect.
-   **Address COVID-19 More Directly:** While you drop 2020 in a robustness check, the pandemic's effects lingered. Consider interacting the `Post` dummy with county-level vaccination rates or COVID mortality as an additional robustness test to ensure your null result isn't confounded by heterogeneous pandemic recovery patterns.

### C. Power and Interpretation
-   **Improve Power Analysis:** The statement "The null is well-powered" is insufficient. Conduct a formal ex-post power calculation or equivalence test. Given your standard errors (~80), what is the minimum detectable effect (MDE) for your preferred specification? Is the MDE small enough to be policy-relevant? The 95% CI of [-210, 110] is quite wide relative to a mean of ~2100; an effect of 110 (5.2% of mean) might still be meaningful.
-   **Clarify the "Standardized Effect Size" Table:** Appendix Table A1 is confusing. "SDE" is not a standard acronym. Explain clearly what it represents (e.g., beta * SD(X) / SD(Y)?). The "Classification" column (e.g., "Small negative") is subjective and should be removed. Focus on the confidence intervals.
-   **Deepen the "Why the Null?" Discussion:** The three explanations provided are good starts. Strengthen them:
    -   *Adaptation:* Provide suggestive evidence. Do major mail-order pharmacies (Express Scripts, CVS) mention operational changes in 2021-22 annual reports? Is there aggregate data on Priority Mail usage for prescriptions?
    -   *90-day Buffers:* Use Medicare Part D data (mentioned in the manifest) to test this directly. Interact treatment with the county-level share of Part D prescriptions filled via 90-day mail order.
    -   *Aggregation Bias:* Acknowledge this as a major limitation more forthrightly. The outcome is a *county-level* rate. If only 10% of a county's Medicare population uses mail-order, even a large effect on that subpopulation would be diluted 10:1. Discuss the need for patient-level analysis.

### D. Presentation
-   **Clarify the "Desert × Post" Result:** The large, negative `Post × pharm_desert` coefficient is intriguing and potentially important. The current explanation ("secular improvement in healthcare access in rural areas") is an afterthought. Explore this further. Is the decline in preventable hospitalizations steeper in pharmacy deserts after 2021? This could be a separate, interesting finding about trends in rural healthcare access unrelated to mail.
-   **Revise Titles and Language:** The title and abstract emphasize the pharmacy desert angle, but the triple-difference is null. Reframe to highlight the overall null finding. Avoid phrases like "delayed amplification pattern observed in my results" (page 7)—the results show no amplification.
-   **Improve Table Readability:** Tables 2 and 3 are poorly formatted. Align decimal points, use consistent significant digit formatting, and ensure notes clearly explain each column. The current presentation is below standard for a top journal.

### E. Additional Robustness Checks
-   **Spatial Correlation:** With only 50 state-level clusters, you may have too few clusters for reliable inference if treatment is spatially correlated within states. Conduct a robustness check with Conley standard errors or spatial HAC estimators to account for potential cross-county correlation.
-   **Placebo Treatments:** The falsification test (Table 5, Col 2) is good. Run additional placebos: randomize the distance thresholds, or apply the treatment assignment logic to earlier periods (e.g., pretend a similar change happened in 2018).
-   **Heterogeneity by Baseline Mail-Order Use:** The manifest's triple-difference uses pharmacy deserts as a proxy for mail-order dependence. A stronger test would use direct data on the county-level share of Medicare Part D prescriptions filled by mail (available from CMS Geographic Variation files). This is a more precise measure of the theoretically affected population.

**Overall:** The paper tackles a novel, policy-relevant question and executes a competent analysis that yields a clear, if unexpected, result. The core task is to shore up the identification by implementing the original, cleaner research design. Doing so will transform the paper from an interesting null into a compelling, credible contribution.
